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Anemia and the Role of the Pharmacist
by Ashlie Kucera, Pharm.D. Candidate Class of 2015; Bethany Smith, Pharm.D. Candidate Class of 2015; 
Laura Tsu, Pharm.D., BCPS; Midwestern University College of Pharmacy – Glendale
Goal:
This home-study CPE has been developed to educate 
pharmacists and pharmacy technicians about the various 
types of anemia and their treatments.
Objectives:
At the conclusion of this lesson, successful participants should 
be able to:
1. Identify signs and symptoms of anemia
2. Differentiate between types of anemia and their etiology
3. Perform patient counseling for oral iron therapy, including 
dosing, drug interactions and side effects
4. List goals of iron therapy 
5. Name food sources rich in iron, folic acid and/or vitamin 
B12
6. Describe treatment of folic acid and vitamin B12 deficiency 
anemias
Introduction
        Anemia, a condition characterized by decreased hemoglo-
bin levels and an insufficient ability to oxygenate the body, is 
one of the most common blood disorders in the world. 
Globally, it affects over 1.6 billion people; roughly 25% of the 
world population.1 
       In healthy individuals, oxygen is adequately transported 
throughout the body via hemoglobin (Hgb), a protein found 
in red blood cells (RBCs). RBCs require several nutrients to 
function properly including iron, folate and vitamin B12. A 
deficiency in any of these nutrients, alteration of morphology 
of the cell, increased RBC destruction or excessive blood loss 
can result in anemia.2 
       There are numerous causes of anemia including 
malnutrition, chronic conditions, pregnancy and drug-induced 
anemia.3 Additional risk factors for anemia include folic acid 
deficiency, vitamin B12 and autoimmune disorders (Table 1.1). 
        Healthy patients with anemia may be asymptomatic if 
their hemoglobin levels decrease slowly over time. Presenta-
tion with acute anemia may present as tachycardia or hypo-
tension, while chronic conditions often present with more 
generalized symptoms like fatigue, weakness or pale skin (Table 
1.2).4,5
Diagnosis
       Although diagnosing anemia may be relatively straight 
forward, a thorough workup is generally required to identify 
the etiology of the disorder. Since there are many different 
causes of anemia it is important to identify the origin of the 
disorder so that it may be treated correctly and can be 
prevented in the future. Usually the assessment begins with 
a detailed history of the patient, including informa-
tion such as diet and lifestyle, medical history, family 
history, current medications and religious practices 
that may influence their diet.6 Next, a physical exam is 
performed and several laboratory tests are complet-
ed.6 Laboratory tests commonly used for the 
diagnosis of anemia include a complete blood count 
(CBC), iron studies, and serum nutrient levels.6,7,8 
Table 1.3 contains common laboratory tests used to 
diagnose anemia and explains what each test assesses. 
There are three broad categories of anemia which are 
differentiated by their mean cell volume (MCV) which 
measures the size of the RBCs. As depicted in Table 
1.3, normal values for MCV range from 80-100 fL/
cell.9 Macrocytic anemias, also known as megaloblastic 
anemias, have a MCV level greater than these values, 
and include folic acid deficiency anemia, vitamin B12 
deficiency anemia and pernicious anemia.10 Microcytic 
anemias have decreased MCV values and include iron 
deficiency anemia. Finally, normocytic anemias have 
MCV values that are within normal limits, and the 
RBCs present in these patients are generally 
unaffected. These anemias are caused by acute blood 
loss or abnormal blood cell production, such as 
aplastic anemia or anemia from chronic renal 
disease.4,11,12 Assessment of a MCV value provides a 
general classification of the anemia and gives the 
provider a better idea of what potential causes may 
be. 
Microcytic Anemias
Iron Deficiency Anemia:
        Iron deficiency anemia, a microcytic anemia6, is 
the most common type of anemia in the world.3 As 
indicated by its name, iron deficiency anemia is the 
result of insufficient iron in the blood. There are 
various causes of iron deficiency, such as insufficient 
consumption in the diet, malabsorption, heavy 
menstruation, pregnancy, dialysis and gastrointestinal 
inflammatory disorders.3,6  On presentation, this type 
of anemia may differentiate from others with 
specific signs and symptoms. These signs include 
tongue soreness or smooth appearance, pica, 
phagophagia, and/or dry mouth.4 Table 2.1 contains 
symptoms of specific anemias. Suspicion of iron de-
ficiency anemia is verified via analysis of iron indices 
and of other labs included in Table 1.3. Patients with 
iron deficiency anemia will have decreased serum iron, 
ferritin and transferrin saturation (TSAT) levels and an 
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increased total iron-binding capacity (TIBC).7  Additionally, 
patients with anemia will frequently show hemoglobin 
levels below 13 g/dL in men and 12 g/dL in women.1
       Once a specific diagnosis of iron deficiency anemia has 
been determined, there are several methods of treatment 
that can be attempted. Generally, mild iron deficiency can 
be treated on an outpatient basis with oral iron replace-
ment therapy, with a goal of 200 mg of elemental iron per 
day. There are currently four oral iron supplements available 
on the market commonly used for treatment: ferrous 
gluconate, ferrous sulfate, ferrous fumarate, and 
polysaccharide iron complex. Table 2.2 describes these oral 
iron products and their elemental iron content. Of these 
four, ferrous sulfate is prescribed most commonly and is 
likely the oral therapy encountered most often in 
community pharmacies.3 
       To ensure that patients get maximum benefit out of oral 
iron therapy, medication counseling should be performed. 
Regimens of iron supplements should be divided into two to 
three doses daily. These supplements should be taken on an 
empty stomach, an hour before meals or two hours 
following a meal. Oral iron has been found to have 
increased absorption when taken with ascorbic acid, so it is 
often recommended that these supplements be taken with 
a glass of orange juice.3 
        Side effects of oral iron therapy are mostly inflicted on 
the gastrointestinal (GI) tract, and include abdominal pain, 
nausea, constipation, heartburn and dark stools. It is 
because of this GI upset that one-time daily dosing should 
be avoided.13,14,15,16  If the patient experiences GI side 
effects that are intolerable, it is recommended that the 
supplements be taken with orange juice and/or food. There 
are several drug-drug interactions of oral iron supplements 
that the pharmacist should be cautious of when filling a 
prescription. Table 2.3 lists these interactions. 
       To assess response to oral iron therapy labs will need 
to be monitored. Reticulocyte count, an assessment of the 
production of new RBCs, should increase within seven to 
ten days. Hemoglobin (Hgb) and hematocrit (Hct) should 
also be tracked with an expected increase in Hgb of 1g/dL 
per week and at least 2g/dL total by three weeks of 
therapy.6 
        Educating patients about dietary sources of iron is an 
important intervention for both treatment of deficiency and 
for preventing future occurrence of anemia. Meat is a good 
source of iron, including red meat, chicken, fish and organ 
meats (i.e. liver). Other sources include beans, green leafy 
vegetables and enriched breakfast cereals. These non-meat 
sources contain “non-heme” iron, which have a lower rate 
of absorption than “heme” iron found in meat. Therefore, 
it is often difficult for vegetarians to achieve recommended 
levels of intake of iron. In this patient population, 
iron-containing dietary supplements may be considered for 
prophylaxis.17 
        In severe cases of iron deficiency anemia, if the 
patient is unable to tolerate oral therapy or if there is 
an inadequate response to oral therapy, parenteral iron 
therapy is indicated.3 There are currently four parenteral 
iron products commonly used: iron dextran, iron sucrose 
and sodium ferric gluconate and ferric carboxymaltose. 
Table 2.4 describes these products and their 
recommended doses. 
        All parenteral iron products have a risk of 
anaphylaxis, with the highest risk associated with iron 
dextran. Due to this high risk, a test dose is required 
prior to administering iron dextran.18 Other adverse 
effects of intravenous iron include arrhythmias, 
arthralgia, hypotension, flushing and prurtitis.18,19,20,21  
Two formulations, iron sucrose and sodium ferric 
gluconate, are only FDA approved for the treatment 
of anemia associated with chronic kidney disease 
(CKD).19,20
Macrocytic Anemias
Vitamin B12 Deficiency and Pernicious Anemias:
       Vitamin B12 deficiency anemia, a macrocytic 
anemia, is one of the most common types of anemia in 
the United States.22 A deficiency of vitamin B12 can be 
caused by several factors, including diet, malabsorption, 
alcoholism, or decreased stomach acidity.23 Certain 
medications can also lead to deficiency such as proton 
pump inhibitors and metformin. A severe form of 
vitamin B12 deficiency is called pernicious anemia. 
Pernicious anemia is a specific type of anemia that is 
caused by autoimmune destruction of gastric parietal 
cells. In healthy individuals these cells produce intrinsic 
factor (IF) which is required to bind and absorb dietary 
vitamin B12. When autoimmune destruction of the 
gastric parietal cells takes place, vitamin B12 can no 
longer be absorbed and deficiency occurs.24
        Specific signs and symptoms differentiate these 
two types of anemia from others such as numbness, 
parasthesias and gait disturbances.23 See Table 2.1 for 
additional symptoms. Development and myelination of 
the central nervous system requires vitamin B12. Thus, 
severe deficiency can result in the presence of 
debilitating neurologic complications.24 Laboratory 
findings to confirm these types of anemias are 
decreased serum vitamin B12 levels and IF, normal 
folate levels, and increased serum methylmalonic acid 
and total homocysteine levels.8 
       Once vitamin B12 deficiency anemia has been con-
firmed, early treatment is important since neurological 
sequelae can be irreversible if not treated in a timely 
manner. Treatment options include replacement therapy 
in a variety of dosage forms, most commonly intramus-
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cular or oral formulations. Generally, parenteral replace-
ment is the preferred method since approximately 10% of 
these doses are absorbed compared to only 0.5-4% of oral 
doses.22 For this reason lower doses of vitamin B12 can be 
given when administered intramuscularly. In order for oral 
therapy to be effective, high doses must be given. Table 3.1 
contains recommended dosing for both oral and parenteral 
vitamin B12 therapies.22, 24
        Lab values and symptoms should be monitored to 
determine response to therapy. Neurological symptoms 
and megaloblastic cells should resolve within a few days, in 
general. An increase in H/H should be noted after about one 
to two weeks of therapy.24 Replacement therapy is usually 
long term for patients without pernicious anemia. For those 
diagnosed with pernicious anemia, lifelong therapy will be 
required.22 CBC and serum vitamin B12 levels should be 
monitored over time, at least 1-2 months after initiation 
of therapy and 3-6 months thereafter.22,24  Side effects of 
replacement therapy include dizziness, headache, anxiety 
or nausea.25 Increased consumption of foods rich in vita-
min B12 can help alleviate deficiency and prevent future 
episodes. Meat, fish, poultry, eggs and dairy products are 
examples of these. As noted previously, increased 
consumption of nutrients such as this can be difficult for 
vegetarians and prophylactic dietary supplementation may 
be indicated.22 
Folic Acid Deficiency Anemia:
       Folic acid deficiency anemia is another common type 
of anemia in the United States. This macrocytic anemia is 
caused by diet, alcoholism, pregnancy and lactation, and 
dialysis. Folic acid deficiency can also be drug-induced and 
may be due to the use of sulfasalazine, methotrexate, 
phenytoin, triamterene, or trimethoprim.3,8,10
        Unique signs and symptoms of folic acid deficiency are 
irritability, personality changes, and memory impairment.17 
Refer to Table 2.1 for additional symptoms. Confirmation of 
this deficiency anemia is obtained by lab values of 
decreased folate levels, and normal vitamin B12, IF and 
methylmalonic acid levels.10 Treatment of this anemia is 
usually accomplished with oral replacement therapy. Table 
3.2 describes common dosing regimens for folic acid 
deficiency anemia. Side effects of replacement therapy are 
generally mild and include malaise, rash and flushing.26 
Green leafy vegetables, citrus fruits, dairy and grains are 
examples of dietary sources rich in folate.17 
Normocytic Anemias
Acute Blood Loss Anemia:
       Hemorrhage and acute blood loss results in anemia due 
to RBC volume depletion. Acute blood loss can occur with 
GI bleeds, trauma or surgery. Symptoms of acute blood 
loss are rapid blood pressure decline and dizziness.5 This is 
categorized as a normocytic anemia since the existing 
RBCs are largely unaffected. Hemoglobin and Hemato-
crit (H/H) are surrogate makers for this type of anemia. 
An elevated reticulocyte count in also noted in these 
patients.17 Refer to Table 1.3 for normal values of these 
labs. Treatment for acute blood loss anemia is generally 
a blood transfusion if the loss is substantial, in addition 
to stopping the source of the bleed.5
Chronic Blood Loss Anemia:
       Anemia in chronic blood loss results from a slow 
downward trend of RBC volume. Conditions such as 
stomach ulcers, diverticulitis, cancers or heavy 
menstrual bleeding are associated with this type of 
anemia. Symptoms include fatigue, shortness of breath 
or paleness.5 Lab values are similar to those of acute 
blood loss and display decreased H/H values.17 
Treatment with blood transfusions for this type of 
anemia may not be indicated; however supplementation 
with iron therapy may be used for several months.5  
Aplastic Anemia:
        Aplastic anemia occurs when a bone marrow 
disorder results in a decreased production of RBCs. 
Other causes of this type of anemia include radiation 
and chemotherapy, exposure to toxins, autoimmune 
disorders, HIV, Epstein-Barr virus, parvo and pregnan-
cy.12 Some medications may also cause aplastic anemia 
such as phenytoin, carbamazepine, chloramphenicol, 
felbamate and quinine.17 Symptoms of this type of 
anemia include fatigue, rapid or irregular heart rate, 
frequent infections, unexplained bruising, nosebleeds 
and bleeding gums, and rash.12 Lab values for aplas-
tic anemia show decreased reticulocyte count, white 
blood cells (WBCs) and platelets.17 For a confirmatory 
diagnosis a bone marrow biopsy is required. Blood 
transfusions, stem cell transplant or pharmacotherapies 
are treatments for this type of anemia.12 Immunosup-
presants such as cyclosporine, methylprednisolone, or 
antithymocyte globulin are examples.12 Bone marrow 
stimulants including filigrastim and epoetin alfa can 
also be used as adjunctive therapy with immunosup-
presants.12 Therapy with antivirals and antibiotics may 
be warranted to prevent infections in these vulnerable 
patients. 
Anemia of Chronic Kidney Disease:
       Patients with chronic kidney disease often exhibit 
anemia due to decreased production of erythropoietin 
by the kidneys. These patients often suffer from weak-
ness, inability to concentrate, chest pain, fatigue, and 
headache.11 Heart failure and tachycardia are common 
complications of this type of anemia.11 Decreased retic-
ulocyte count and normal or increased WBCs and 
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platelets are often seen in this patient population.17 
Additional testing may include H/H, ferritin and TSAT 
levels.11,17 Common treatments involve erythropoietin, iron 
supplementation, blood transfusions, and vitamin B12 and 
folate supplementation.11
Other Anemias
        Another form of anemia is anemia of chronic disease. 
Also called “anemia of inflammation”, this disorder is due to 
conditions such as rheumatoid arthritis, lupus, cancer, HIV, 
and inflammatory bowel disease.27 When severe, this type 
of anemia resembles iron deficiency anemia.27 Symptoms 
are general, see Table 1.2 for a list. Suspected cases of this 
type of anemia are generally confirmed by detection of an 
increased level of cytokines. Other lab values include 
decreased MCV and TIBC, increased TSAT, and normal/el-
evated serum iron and ferritin.17,27 Treatment options for 
anemia of chronic disease include blood transfusions, eryth-
ropoietic agents, and iron therapy if deficiency is present.27
        There are several other types of anemia which are less 
common.  Two examples of these are sickle cell anemia 
and myeloplastic anemia which will not be discussed in the 
article.
Pharmacist’s Role
       The pharmacist has a critical role in the treatment of 
patients with anemia. Pharmacists can assist patients with 
therapy management, particularly in areas of iron admin-
istration, dietary recommendations, drug interactions with 
oral iron, and medications that can exacerbate conditions. 
As pharmacists, we should also be aware of the signs and 
symptoms of anemia in order to assess efficacy of treatment 
and refer those patients who need to seek medical 
attention. Pharmacists can utilize their extensive 
pharmacological knowledge to increase positive outcomes 
in our patients. 
 
Chronic Conditions Drug-induced Miscellaneous 
Crohn's Disease Aspirin Folic acid deficiency 
Ulcerative colitis NSAIDS Vitamin B12 deficiency 
Rheumatoid Arthritis PPIs Pregnancy 
Autoimmune disorders H2RAs Lactation 
Cancer Antacids Heavy menstruation 
Liver disease Trimethoprim Reduced stomach acid 
Thyroid disease Triamterene Poor diet 
Chronic Kidney Disease Methotrexate Malnutrition 
Dialysis Phenytoin Infection 
Alcoholism Sulfasalazine Children 
Table 1.1. Risk factors for anemia. 
PPIs=proton pump inhibitors 
H2RAs=histamine 2 receptor antagonists 
 
Acute Chronic 
Tachycardia Asymptomatic 
Palpitations Fatigue 
Angina Weakness 
Hypotension Headache 
Light-headedness Sensitivity to cold 
Shortness of breath Pale and yellow skin 
"Whooshing" sound in ears  
Table 1.2. General signs and symptoms of anemia.  
 
 
 
 
CBC  Iron 
Studies 
 RBC 
Indices 
 Other  
Hgb M: 14-17 
g/dL 
F: 12-15 g/dL 
Serum 
Iron 
M: 46-160 
mcg/dL 
F: 30-160 
mcg/dL 
 MCV 80-100 
fL/cell 
Vitamin B12 180-660 pg/mL 
Hct M: 42-50% 
F: 36-45% 
Serum 
Ferritin 
12-300 ng/mL  MCH 27-33 
pg/cell 
Plasma Folate 3.4-12.4 mcg/L 
RBC 
count 
M: 4.5-6 x 
106 cell/mL 
F: 4-5 x 106 
cell/mL 
TIBC 
 
TSAT 
220-420 mcg/dL 
 
30-50% 
MCHC 33.4-
35.5% 
Reticulocyte 
count 
 
RBC 
distribution 
width 
M: 0.5-1.5% 
F: 0.5-2.5% 
 
14.5-15.5% 
        
      Schilling test 
(intrinsic factor) 
10% excretion of 
radiolabeled B12 
        
      Methylmalonic 
acid 
0.08-0.56 mcmol/L 
        
      Homocysteine 4-17 mcmol/L 
Table 1.3. Common anemia laboratory parameters and normal ranges. 
CBC=complete blood count 
Hgb=hemoglobin 
Hct=hematocrit 
RBC=red blood cell 
M=male 
F=female 
TIBC=total iron binding capacity 
TSAT=transferritin saturation 
MCV=mean cell volume 
MCH=mean cell hemoglobin 
MCHC=mean cell hemoglobin concentration 
 
 
Iron Deficiency Vitamin B12 Deficiency Folate Deficiency 
Sore mouth Numbness/parasthesia Irritability 
Smooth tongue Imbalance (gait disturbance) Personality changes 
Pica Personality changes Depression 
Pagophagia Swollen/inflamed tongue Memory impairment 
Reduced saliva Depression Mouth sores 
Table 2.1. Signs and symptoms for specific types of anemia. 
 
 
 
Agent Percent Elemental 
Iron 
Elemental Iron/Dose Form 
Ferrous gluconate 12% 39 mg/325 mg tablet 
37 mg/300 mg tablet 
Ferrous sulfate 20% 65 mg/325 mg tablet 
60 mg/300 mg tablet 
44 mg/5 mL elixir 
 
Ferrous fumarate 
 
33% 33 mg/100 mg tablet 
Polysaccharide-iron 
complex 
100% 150 mg/capsule 
50 mg/tablet 
   
Table 2.2. Oral iron products. 
 
 
 
 
Decrease iron absorption Medications affected by 
iron 
Gastric acid suppressants 
(antacids, PPIs) 
 
Cholestyramine 
 
Tetracycline/doxycycline 
Levodopa/methyldopa 
 
Levothyroxine 
 
Bisphosphonates 
 Fluoroquinolones 
  
 Tetracycline/doxycycline 
Table 2.3. Drug-drug interaction with oral iron products. 
PPIs=proton pump inhibitors 
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Agent Recommended Dosing  
Iron sucrose Non-dialysis: 200 mg administered on 5 different occasions within 14 days 
totaling 1000 mg in 14 days 
Iron dextran Dose (mL) = 0.0442 (desired Hgb - observed Hgb) x LBW + (0.26 x LBW), with 
desired hemoglobin at 14.8 g/dL and LBW= lean body weight; test dose of 0.5 ml 
should be given 
Sodium ferric gluconate 125 mg elemental iron per dialysis session. Most patients will require a 
cumulative dose of 1 g elemental iron over approximately 8 sequential dialysis 
treatments to achieve a favorable response 
Ferric carboxymaltose <50 kg: 15 mg/kg elemental iron on day 1; repeat dose after at least 7 days 
(maximum: 1500 mg elemental iron per course). May repeat course of therapy if 
anemia reoccurs 
≥50 kg: 750 mg on day 1; repeat dose after at least 7 days (maximum: 1500 mg 
per course). May repeat course if anemia reoccurs 
Table 2.4. Parenteral iron products.  
 
 
 
Agent Dosing Adverse Drug Reactions 
Vitamin B12: 
Oral B12 
 
IM B12 injections 
 
1000-2000 mcg/day 
 
Start with 8-10 loading  
doses of 1000 mcg several 
times 1 week (if severe), 
taper to 1000 mcg /month 
 
Nausea, nervousness, dizziness, headache, 
edema, itching, diarrhea, rhinitis, dysnpea, 
peripheral vascular thrombosis, avoid if 
allergic to cyancobalamin or cobalt 
Table 3.1. Recommended dosing for vitamin B12. 
IM=intramuscular 
  
 
Agent Dosing Adverse Drug Reactions 
Folate: 
Folic acid  
(PO, IV, IM, SQ) 
 
Adults: 0.4 mg/day 
Pregnancy: 0.8/day 
 
Malaise, flushing, rash, erythema, 
bronchospasm 
Table 3.2. Recommended dosing for folate. 
PO=oral 
IV=intravenous 
IM=intramuscular 
SQ=subcutaneous 
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